Analgesics & rebound headache
This article was originally published in The Tan Sheet
Executive Summary
Chronic use of OTC analgesics that can lead to "rebound headache" may be situation "where we need to improve the labeling and get better information out to consumers so that they can avoid the problem," FDA Commissioner Mark McClellan, MD/PhD, suggests during Jan. 15 appearance on National Public Radio's Diane Rehm Show. If consumers "are using the product very frequently for headaches, they probably should contact their health professional to see if there is another cause for the recurrent headaches, or if there is a better treatment available," he adds. McClellan's comments were prompted by article suggesting link between rebound headache and analgesic use in the Jan. 12 New York Times. Segment on the issue also aired on ABC TV's 20/20 program Jan. 10...
You may also be interested in...
Setback For Athenex, Hanmi As CRL Requests New Trial
Hanmi partner Athenex has had a US complete response letter for its oral paclitaxel plus encequidar product for the treatment of metastatic breast cancer, amid concerns of safety risks associated with an increase in neutropenia-related sequelae. While the decision marks another setback for Hanmi in the US, Athenex is aiming to resolve the issues.
Chordia Looks To Forge Own Path In Oncology
Chordia only came into being in late 2017 but has already struck its first major licensing-out deal with a major pharma firm. It is now looking ahead to taking forward a portfolio of novel oncology assets originally acquired from investor Takeda.
Reimbursement Questions Jeopardize Hillrom/Bardy Merger
Hillrom is reconsidering its planned $375m acquisition of Bardy Diagnostics because of Novitas' plan to cut Medicare reimbursement for extended cardiac monitoring. Bardy is suing to complete the deal.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: